**CALR** type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients

Philip Weir1,2, Andrew Hindley1, Mark Catherwood1, Mary Frances McMullin3

Received: 31 March 2022 / Accepted: 2 June 2022 / Published online: 7 June 2022

© The Author(s) 2022

**Abstract**

**Background** Calreticulin (**CALR**) mutations are commonly identified in patients with essential thrombocythaemia or myelofibrosis. **CALR** type 1 mutations are known to have a higher overall incidence in males but little is known about the risks of mutation subtypes on myelofibrotic change across patient age and sex.

**Aims** To identify differences in the incidence of myelofibrotic change within subgroups of patients with **CALR** type 1 mutations.

**Methods** All patients with a positive **CALR** exon 9 mutation identified within our unit between February 2016 and September 2020 were reviewed with note taken of patient sex, age at diagnosis, initial MPN diagnosis, and subsequent disease transformation.

**Results** In our cohort, young male patients with **CALR** type 1 mutations were shown to be at significantly increased risk of myelofibrosis compared to age matched female patients.

**Conclusions** Male patients have a worse myeloproliferative neoplasm phenotype than female patients with it occurring at a younger age and being more myelofibrotic in nature. Further investigation is needed into the reasons for this variability.

**Keywords** **CALR** · Essential thrombocythaemia · MPN · Myelofibrosis · Myeloproliferative neoplasm

**Introduction**

Calreticulin (**CALR**) exon 9 mutations are the second most common mutations in patients with essential thrombocythaemia (ET) and primary myelofibrosis (PMF). The overall risk of myelofibrotic change, either PMF or secondary myelofibrosis (SMF), appears to be more frequent in patients with **CALR** type 1 than type 2 mutations [1] and male patients are more likely than females to have **CALR** type 1 mutations [2].

It had been noted locally that a significant number of young male patients with **CALR** mutations appeared to have a more aggressive/myelofibrotic disease phenotype. The aim of this study was to identify if there were further differences in the incidence of myelofibrotic change within subgroups of patients with **CALR** mutations, specifically looking to see if males with **CALR** type 1 mutations were more likely to have myelofibrosis than females and if they developed it at a younger age.

**Methods**

The study reviewed all patients with a positive **CALR** exon 9 mutation identified within our unit between February 2016 and September 2020. **CALR** mutations were identified as previously described [3]. Mutation sub-types were identified and compared with patient sex, age at diagnosis, initial MPN diagnosis, and subsequent disease transformation. Statistical analysis was performed with *p*-values for the total male and female patients with myelofibrosis within each age group calculated using Fisher’s exact test.

**Results**

**CALR** type 1 mutations (including type 1-like mutations throughout) or type 2 mutations were identified in 123 patients and were overall more frequent in males (74 male, 49 female,
p = 0.024) as shown in Table 1. Seventy-five (61.0%) of these patients had CALR type 1 mutations and 48 (39.0%) type 2. The incidence of CALR type 2 mutations in male compared with female patients were significantly higher in those under the age of 60 but not different in those over 60; however, further detailed analysis of myelofiбросic variances in CALR type 2 mutations was prevented by low patient numbers within each subgroup.

Of the 44 male patients with CALR type 1 mutations, 9 were diagnosed with PMF and 35 with ET. Twelve of those with ET subsequently transformed to SMF. Thirty-one female patients had CALR type 1 mutations with 5 of these being diagnosed with PMF and 26 with ET. Two transformed to SMF. The overall risk of myelofiбросis in patients with CALR type 1 mutations was therefore significantly higher in male than in female patients with 21 of 44 (47.7%) versus 7 of 31 (22.6%), respectively, p = 0.0315.

Whilst the overall risk of myelofiбросis with CALR type 1 mutations is highest in males, this risk appears to vary between age groups. The mean age of developing myelofiбросis, either PMF or SMF, in the cohort was 61 overall with it being 59 for males and 66 for females. The median was 62 overall with a median age of 60 for males and 65 for females. These findings indicate that myelofiбросis occurs at a younger age in male patients who have CALR type 1 mutations.

To consider this further, the data was split by age group and is summarised in Table 1. Of the 32 patients aged 60 or over with CALR type 1 mutations, 19 were male and 13 were female. Eight of the male and 3 of the female patients had myelofiбросis. Whilst in keeping with the known increased frequency of males having CALR type 1 mutations, the risk of myelofiбросis between sexes was not statistically different in this older age group, p = 0.4501.

The risk of myelofiбросis was also not quite statistically different when looking at those with CALR type 1 mutations under 60 years of age overall at 0.0637; however, myelofiбросis became increasingly common in the male sex among younger age groups. Of the 18 patients under 50 years old, 13 were male and 5 were female. All females had ET without progression but 9 of the males had developed myelofiбросis, p = 0.0294. Of the 7 patients under 40 years old, the 2 females had ET but all 5 males had myelofiбросis, p = 0.0476.

**Discussion**

This study highlights that in our cohort, CALR type 1 mutations are associated with an overall increased incidence of myelofiбросis in male compared with female patients. This variation is particularly evident in those diagnosed at a young age where despite low patient numbers, there is a statistically increased risk of myelofiбросis among male patients under the age of 40 which persists in those under 50 but becomes less relevant in those diagnosed later in life.

| Table 1 | Diagnoses (initial and subsequent) by age of male and female patients with CALR mutations |
|---------|---------------------------------------------------------------------------------------------|
| Male (M) | Female (F)                                                                                   |
| **MPN subtypes** | **Total patients** | **Total Age < 40** | **Age < 50** | **Age < 60** | **Age 60+** | **Total Age < 40** | **Age < 50** | **Age < 60** | **Age 60+** | **Total Age < 40** | **Age < 50** | **Age < 60** | **Age 60+** |
| CALR type 1 | All | 75 | 44 | 13 | 19 | 31 | 2 | 5 | 18 | 10 | 0.1333 | 0.2568 | 0.0593 | 0.2888 |
| | Initially ET | 61 | 35 | 8 | 18 | 26 | 2 | 5 | 0 | 2 | - | - | - | - |
| | PMF | 14 | 9 | 4 | 2 | 2 | 5 | 0 | 0 | 2 | - | - | - | - |
| | SMF | 14 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - |
| | Total MF | 28 | 13 | 8 | 18 | 18 | 2 | 0 | 0 | 1 | - | - | - | - |
| CALR type 2 | All | 48 | 30 | 12 | 9 | 18 | 12 | 17 | 11 | 4 | 0.0833 | 0.2568 | 0.0593 | 0.2888 |
| | Initially ET | 46 | 19 | 4 | 9 | 18 | 17 | 11 | 1 | 4 | 0.0050 | 0.0175 | 0.0593 | 0.2888 |
| | PMF | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | - | - | - | - |
| | SMF | 5 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | - | - | - | - |
| | Total MF | 7 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | - | - | - | - |

Bold font indicates p-values of significance.
In our cohort, all 9 patients with myelofibrosis under the age of 50 were male and this finding does not appear to be an outlier. Although not specifically investigated in their study, previously published data by Cabagnols et al. [4] showed a similar trend in their cohort, with males accounting for 83.3% of patients under 50 with both CALR type 1 mutations and myelofibrosis. This was despite them making up only 53.4% of CALR type 1 mutation positive patients overall.

The reason for these variations in incidence and MPN phenotype in younger age groups is not currently understood but may relate to hormonal variations. The incidence of myelofibrosis between male and female patients being significantly different in those under 50 years old but not significant beyond this age appears to correlate with the age of menopause.

High oestrogen levels present in premenopausal females may be protective against both CALR type 1 mutation or allele burden, and transformation to myelofibrosis. Tamoxifen, a selective oestrogen receptor modulator, has long been known to exhibit a complex spectrum of both oestrogen agonistic and antagonistic effects depending on the specific tissue affected [5]. The recent Tamarin study showed that tamoxifen could induce apoptosis of CALR mutated hematopoietic progenitors, and based on preclinical studies, this appeared to work by modulation of oestrogen receptor alpha [6]. It remains unclear if Tamoxifen’s modulatory role in this area is oestrogen agonistic or antagonistic, but these results give further weight to oestrogen’s relevance in MPN associated with CALR mutations.

**Conclusion**

Whilst it is already known that CALR type 1 mutations are more common in males, this study is the first to demonstrate that even within the demographic of those with CALR type 1 mutations, male patients have a worse MPN phenotype than female patients with it occurring at a younger age and being more myelofibrotic in nature. The potential reasons for this variability as discussed could lead to new opportunities for treatment and warrant further investigation.

**Declarations**

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Pietra D, Rumi E, Ferretti VV et al (2016) Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 30(2):431–438
2. Tefferi A, Wassie EA, Guglielmelli P et al (2014) Type 1 versus type 2 calreticulin mutations in essential thrombocytemia: a collaborative study of 1027 patients. Am J Hematol 89(8):E121–E124
3. Catherwood MA, Graham A, Cuthbert RJG et al (2018) Absence of CALR mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Acta Haematol 139(4):217–219
4. Cabagnols X, Defour JP, Ugo V et al (2015) Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia 29(1):249–252
5. Horner-Glister E, Maleki-Dizaji M, Guerin CJ et al (2005) Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells. J Mol Endocrinol 35(3):421–432
6. Harrison C, Baxter J, Boucher RH et al (2020) Effects of tamoxifen on the mutant allele burden and disease course in patients with myeloproliferative neoplasms - results of the Tamarin Study. Blood 136(Supplement 1):33–35

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.